62 231

Cited 40 times in

Effects of omalizumab treatment in patients with refractory chronic urticaria

Authors
Nam, YH; Kim, JH; Jin, HJ; Hwang, EK; Shin, YS; Ye, YM; Park, HS
Citation
Allergy, asthma & immunology research, 4(6):357-361, 2012
Journal Title
Allergy, asthma & immunology research
ISSN
2092-73552092-7363
Abstract
PURPOSE: Chronic urticaria (CU) is a common and debilitating disease, and the need for effective treatment has increased. Omalizumab may be an alternative regimen in patients with CU who do not respond to conventional treatments. The aim of this study is to investigate the efficacy and to observe the clinical results of omlizumab in patients with refractory CU.



METHODS: We conducted a retrospective analysis of 26 patients with refractory CU who were treated with omalizumab. Omalizumab was administered every 2 or 4 weeks, depending on body weight and the total serum IgE level, for 24 weeks.



RESULTS: Fourteen patients (53.8%) achieved remission after the treatment; they had a significantly higher prevalence of personal (P=0.033) and family history of allergic diseases (P=0.002) than those who did not achieve remission. During omalizumab treatment, the urticaria activity score declined significantly (12.11±1.97 to 2.7±4.23; P=0.001) and the CU-quality of life score improved significantly (34.65±13.58 to 60.88±11.11; P=0.004). There were significant decreases in the use of systemic steroids (42.3%-11.5%; P=0.027) and immunomodulators (65.4%-19.2%; P=0.002). The dose of antihistamines required to control CU also decreased significantly (215.66±70.06 to 60.85±70.53 mg/week of loratadine equivalents; P<0.001). No serious adverse event was noted.



CONCLUSIONS: These findings suggest that omalizumab can be an effective and safe treatment in patients with refractory CU.
DOI
10.4168/aair.2012.4.6.357
PMID
23115733
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Allergy
AJOU Authors
신, 유섭예, 영민박, 해심
Full Text Link
Files in This Item:
357-361.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse